This retrospective analysis evaluated whether serum cardiac troponin T (cTnT) may serve as a biomarker of treatment response in patients with SOD1-associated amyotrophic lateral sclerosis (ALS) treated with tofersen.
This retrospective analysis evaluated whether serum cardiac troponin T (cTnT) may serve as a biomarker of treatment response in patients with SOD1-associated amyotrophic lateral sclerosis (ALS) treated with tofersen.